Showing results (1211-1220 of 1,342) with videos related to

Sort By:
Pageof 135
Neuro-Oncology Advances|September 22, 2025
A randomized controlled trial of a telehealth group cognitive intervention (LaTCH-BRAINS) to improve cognition after primary brain tumor diagnosisKerryn E Pike, Sian E B Virtue-Griffiths, Rachel Campbell, et al.
Neuro-Oncology Advances|September 22, 2025
Effect of focused ultrasound-induced mechanical ablation on stemness and dormancy properties of residual/peri-focally localized glioblastoma cellsDana Hellmold, Levi Johanning, Jacqueline Clüver, et al.
Neuro-Oncology Advances|September 22, 2025
Revisiting pediatric HGGs and PNETs according to the WHO CNS5 criteria: A clinical and genomic retrospective analysisJoo Whan Kim, Seung Ah Choi, Sungyoung Lee, et al.
Neuro-Oncology Advances|September 22, 2025
Assessing the clinical benefit from medical therapies in CNS malignancies: Refining the ESMO Magnitude of Clinical Benefit Scale and the ASCO Value FrameworkSylvia C Kurz, Mirjam Renovanz, Michael Bitzer, et al.
Neuro-Oncology Advances|September 22, 2025
The relationship between deviant brain activity and executive functioning in glioma patientsMona L M Zimmermann, Christina Ulrich, Lucas C Breedt, et al.
Neuro-Oncology Advances|May 16, 2025
Chimeric antigen receptor-macrophages: Emerging next-generation cell therapy for brain cancerMyrthe J A Koppers, Matthijs Monnikhof, Jan Meeldijk, et al.
Neuro-Oncology Advances|May 16, 2025
The immunopeptidomic landscape of ependymomas provides actionable antigens for T-cell-based immunotherapyLena Mühlenbruch, David Rieger, Hannes Becker, et al.
Neuro-Oncology Advances|May 16, 2025
Effects of craniectomy defect on tumor-treating fieldsEdwin Lok, Bryant Chang, Rafael Vega, et al.
Neuro-Oncology Advances|May 12, 2025
Adverse neurologic events of immune checkpoint inhibitor monotherapy vs. combination therapy for melanomaNikita Das, Ravi Dhamija, David C Kaelber, et al.
Neuro-Oncology Advances|May 12, 2025
Alzheimer's disease neuropathological change in younger individuals with IDH-mutant gliomaLisa Greutter, Lisa Schnitzenlehner, Sigrid Klotz, et al.
Pageof 135